Literature DB >> 19484483

Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.

Lale Atahan1, Ferah Yildiz, Mustafa Cengiz, Bunyamin Kaplan, Metin Ozkan, Gozde Yazici, Mete Gündoğ, Ayfer Haydaroğlu, Aylin F Korcum, Meriç Sengöz, Maktav Dinçer, Müge Akmansu, Kayihan Engin, Mutlu Hayran.   

Abstract

INTRODUCTION: In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated.
MATERIALS AND METHODS: Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. RESULTS AND
CONCLUSION: No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484483     DOI: 10.1007/s00520-009-0663-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  38 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Management of bone metastases in breast cancer.

Authors:  Allan Lipton
Journal:  Curr Treat Options Oncol       Date:  2005-03

3.  Alendronate disturbs vesicular trafficking in osteoclasts.

Authors:  A Alakangas; K Selander; M Mulari; J Halleen; P Lehenkari; J Mönkkönen; J Salo; Kalervo Väänänen
Journal:  Calcif Tissue Int       Date:  2001-12-21       Impact factor: 4.333

4.  Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.

Authors:  S Boissier; S Magnetto; L Frappart; B Cuzin; F H Ebetino; P D Delmas; P Clezardin
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

5.  Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

Authors:  William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

Review 6.  Bisphosphonates for breast cancer.

Authors:  N Pavlakis; Rl Schmidt; M Stockler
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

7.  Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis.

Authors:  Sarah A Arrington; Timothy A Damron; Kenneth A Mann; Matthew J Allen
Journal:  J Surg Oncol       Date:  2008-03-01       Impact factor: 3.454

8.  Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.

Authors:  P Price; P J Hoskin; D Easton; D Austin; S G Palmer; J R Yarnold
Journal:  Radiother Oncol       Date:  1986-08       Impact factor: 6.280

9.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

Authors:  Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

10.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Authors:  S P Jagdev; R E Coleman; C M Shipman; A Rostami-H; P I Croucher
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

View more
  6 in total

Review 1.  Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.

Authors:  Donald L Patrick; Charles S Cleeland; Roger von Moos; Lesley Fallowfield; Rachel Wei; Katarina Öhrling; Yi Qian
Journal:  Support Care Cancer       Date:  2014-12-23       Impact factor: 3.603

2.  Reporting characteristics of cancer pain: a systematic review and quantitative analysis of research publications in palliative care journals.

Authors:  Senthil P Kumar
Journal:  Indian J Palliat Care       Date:  2011-01

Review 3.  Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.

Authors:  H Shibata; S Kato; I Sekine; K Abe; N Araki; H Iguchi; T Izumi; Y Inaba; I Osaka; S Kato; A Kawai; S Kinuya; M Kodaira; E Kobayashi; T Kobayashi; J Sato; N Shinohara; S Takahashi; Y Takamatsu; K Takayama; K Takayama; U Tateishi; H Nagakura; M Hosaka; H Morioka; T Moriya; T Yuasa; T Yurikusa; K Yomiya; M Yoshida
Journal:  ESMO Open       Date:  2016-03-16

Review 4.  Therapeutic Irradiation: Consequences for Bone and Bone Marrow Adipose Tissue.

Authors:  Samantha Costa; Michaela R Reagan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-29       Impact factor: 5.555

5.  Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy: A Systematic Review.

Authors:  Alexander Fabian; Justus Domschikowski; Anne Letsch; Claudia Schmalz; Sandra Freitag-Wolf; Juergen Dunst; David Krug
Journal:  JAMA Netw Open       Date:  2022-09-01

6.  Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?

Authors:  Carsten Nieder; Adam Pawinski; Astrid Dalhaug
Journal:  Radiat Oncol       Date:  2013-04-10       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.